Significance of genetic alterations and glycosylation in PD-L1 and their biomarker development
Project/Area Number |
17K09638
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Hokkaido University |
Principal Investigator |
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 非小細胞肺癌 / PD-L1タンパク質発現 / PD-L1遺伝子変異 / PD-L1遺伝子変異解析 / 内科 / ゲノム / 糖鎖 |
Outline of Final Research Achievements |
We explored new biomarkers in non-small cell lung cancers (NSCLCs). We studied PD-L1 expression by IHC in 154 surgically resected NSCLC specimens, and found H score > or = 10% in 46.8 % of specimens, which were associated with squamous cell carcinoma compared with adenocarcinoma, and with smoking. We studied SNP in PD-L1 3’UTR miRNA seeding region by NGS in 126 surgically resected NSCLC specimens, and found higher PD-L1 expression in the cancer/normal-matched group (52/114) than the cancer/normal-mismatched group (10/12) (P = 0.01).
|
Academic Significance and Societal Importance of the Research Achievements |
抗PD-1/PD-L1抗体薬の治療効果予測因子は、肺癌においてはPD-L1免疫染色であるが、同一腫瘍内の不均一性や臨床経過による変化があり、より“固定的で安定な”治療効果予測因子の開発が求められる。本研究では、PD-L1遺伝子の遺伝子変異(SNP)に着目し、新たなバイオマーカー(抗PD-1/PD-L1抗体薬の治療効果予測因子)を探索した意義は極めて大きく、今後、肺癌のみならず、肺癌以外の癌腫においても参考になるものと考えられる。
|
Report
(4 results)
Research Products
(1 results)